在现场形成的聚植入物用于持续的静脉内氧丁宁释放
Michael Uwe Hartig1,2, Jan Appelhaus1, Marc Vollenbröker2
1Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany.
Pharmaceutics
|November 27, 2025
概括
一种针对神经性排毒器过活性的新型生物降解植入物 (NDO) 可提供为期一周的治疗,减少了导管治疗的需要. 这种持续释放的配方改善了NDO患者的生活质量.
科学领域:
- 生物材料科学 生物材料科学
- 聚合物化学 聚合物化学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 神经源性排毒剂过度活动 (NDO) 导致膀功能障碍,原因是神经疾病,如脊髓损伤.
- 目前的治疗包括频繁的导管和口服药物,如氧丁宁化.
- 对于NDO患者来说,需要改进,更少的侵入性治疗选择.
研究的目的:
- 研究一种在位形成植入物 (ISFI) 的新型植入物,用于在尿膀中持续释放氧丁宁化.
- 量化药物释放,聚合物降解和溶剂释放,用于基于PLGA的配方.
- 为了确定影响药物释放和聚合物降解的配方参数,用于NDO治疗.
主要方法:
- 基于PLGA的ISFI的开发和体外测试,具有不同的药物负载和聚合物终结.
- 随着时间的推移,氧丁宁化释放概况的量化.
- 使用不同的配方和药物度评估PLGA聚合物降解率.
- 评估溶剂释放特性.
主要成果:
- 药物负载和PLGA终止显著影响了药物释放和聚合物降解.
- 增加药物负载 (1.5%至7.5%) 增强了PLGA降解.
- 氧化丁基催化聚合物降解;与以乙烯为终结的相比,酸终结的PLGA降解增加.
- 确定了配方参数,以控制药物释放和聚合物降解.
结论:
- 可生物降解的ISFI是NDO治疗的可行性,可能允许一次性管理长达一周.
- 这种新型的植入物可以通过减少治疗负担,显著提高NDO患者的生活质量.
- 了解配方参数是优化药物释放和聚合物降解以获得有效的NDO治疗的关键.
相关概念视频
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...